MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, announces the Company will participate in the 16th Annual Mount Sinai Winter Dermatology Symposium in New York City, December 6-8, 2013. In conjunction with the Symposium, MELA will also host its second Clinical Advisory Meeting on Friday, December 6, 2013. The Mount Sinai Symposium focuses on the most current research, devices, surgical techniques, cosmetic agents and diagnosis and treatment techniques for a variety of skin conditions, including skin cancer. The symposium is intended for...
↧